- Home
- HCA vs SNY Comparison
HCA vs SNY Comparison
Compare HCA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | SNY |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5B | 107.3B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | SNY |
|---|---|---|
| Price | $481.57 | $47.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $528.00 | $58.00 |
| AVG Volume (30 Days) | 822.9K | ★ 2.9M |
| Earning Date | 04-24-2026 | 04-23-2026 |
| Dividend Yield | 0.64% | ★ 3.33% |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 28.33 | N/A |
| Revenue | ★ $75,600,000,000.00 | N/A |
| Revenue This Year | $5.07 | $3.86 |
| Revenue Next Year | $4.90 | $5.64 |
| P/E Ratio | $17.29 | ★ $6.14 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $314.43 | $43.32 |
| 52 Week High | $556.52 | $55.73 |
Technical Indicators
Market Signals| Indicator | HCA | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 58.76 |
| Support Level | $461.11 | $46.88 |
| Resistance Level | $519.90 | $48.49 |
| Average True Range (ATR) | 12.77 | 0.71 |
| MACD | 1.49 | 0.12 |
| Stochastic Oscillator | 45.43 | 74.45 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.